CPHI Online Report - Pharma Market Trends 2021
Pharma Market Trends 2021
Twelve pharma market trends we anticipate across 2021 for the drug development, manufacturing and outsourcing sectors.
2020 has been one of the most turbulent years in recent history and has cast a shroud of uncertainty over the future. While pharmaceutical companies have proved instrumental in responding to the pandemic through innovation, collaboration and manufacturing expertise, COVID-19 has also raised fresh challenges for the industry to overcome.
In this trend report, we explore the key opportunities, disruptors and dynamics which the industry will face throughout 2021.
Pharma’s response to the pandemic in terms of vaccines development and distribution of treatments has grabbed the majority of the headlines but the major issues facing the industry are by no means exclusively coronavirus related.
In interviews with key industry experts, this report identifies key trends that we anticipate throughout 2021, as pharmaceutical manufacturing and outsourcing continue to respond not only to the challenges that the ongoing global crisis has presented, but also to evolving obstacles and hurdles that are typical in such a highly-regulated sector.
Key pharma market trends for 2021:
- Supply chain resilience to take precedence over reshoring of active pharmaceutical ingredient manufacturing
- Pandemic accelerates digital transformation of API sourcing and trading
- Suppy chain security and patient centricity focus
- Cure vs. treatment model shifts CDMO contracts from volume to value
- A gradual breakthrough for continuous manufacturing of APIs
- COVID-19 vaccines to take central stage
- Vaccine distribution and roll-out
- Industry fight against antimicrobial resistance to gain prominence
- Enablers of precision medicine: next-generation sequencing
- Continuing consolidation in the pharma contract services sector
- Emerging pharma markets will be key to expansion of pharma and biopharma capabilities
- Rise in biosimilar applications due to patent expiries
Click the link at the bottom of this page to download the complete CPHI Pharma 2021 Trends Report
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...